Don't Blame the Pigeons for Aspergillosis
Let's take a closer, more informed look.
What is Aspergillosis, Really?
Aspergillosis is an infection caused by Aspergillus — a genus of mold that includes hundreds of species. The most common culprit in infections is Aspergillus fumigatus, a fungus that produces tiny airborne spores. These spores, when inhaled in large quantities, can cause respiratory illness, especially in individuals with weakened immune systems, preexisting lung conditions, or prolonged exposure to dusty, moldy environments.
However, here's the critical fact: Aspergillus is ubiquitous. It's found everywhere — in soil, decaying vegetation, compost, dust, old building materials, air-conditioning systems, bird droppings, and even in grain and spices. It thrives in damp and poorly ventilated areas. The spores are so widespread that avoiding them entirely is virtually impossible. Inhaling a few spores is a part of daily life and is generally harmless to healthy individuals.
Pigeons Are Not the Sole Source — Far From It
Despite popular belief, pigeons are not the origin of aspergillosis. While the droppings of any bird — including pigeons — can provide a damp organic medium where mold might grow, this is no different from a damp corner of a bathroom, an uncleaned air duct, or neglected plant soil. The link between pigeons and the fungus is indirect at best. The presence of pigeons may coincide with mold-friendly conditions, but they are not the cause.
Blaming pigeons alone for spreading a naturally occurring mold is scientifically unfounded. The real issue is environmental hygiene, not avian biology.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
12 hours ago
- New Indian Express
Don't Blame the Pigeons for Aspergillosis
In recent times, the blue rock pigeon — also known as Columba livia — has found itself at the center of a growing controversy. Commonly seen flitting about on balconies, rooftops, and urban ledges, this resilient bird is now being scapegoated for an illness called aspergillosis. This respiratory infection, caused by fungi from the Aspergillus genus, has sparked headlines and concerns, leading many to point fingers squarely at these pigeons as disease carriers. But is this accusation fair, or is it a case of misplaced blame? Let's take a closer, more informed look. What is Aspergillosis, Really? Aspergillosis is an infection caused by Aspergillus — a genus of mold that includes hundreds of species. The most common culprit in infections is Aspergillus fumigatus, a fungus that produces tiny airborne spores. These spores, when inhaled in large quantities, can cause respiratory illness, especially in individuals with weakened immune systems, preexisting lung conditions, or prolonged exposure to dusty, moldy environments. However, here's the critical fact: Aspergillus is ubiquitous. It's found everywhere — in soil, decaying vegetation, compost, dust, old building materials, air-conditioning systems, bird droppings, and even in grain and spices. It thrives in damp and poorly ventilated areas. The spores are so widespread that avoiding them entirely is virtually impossible. Inhaling a few spores is a part of daily life and is generally harmless to healthy individuals. Pigeons Are Not the Sole Source — Far From It Despite popular belief, pigeons are not the origin of aspergillosis. While the droppings of any bird — including pigeons — can provide a damp organic medium where mold might grow, this is no different from a damp corner of a bathroom, an uncleaned air duct, or neglected plant soil. The link between pigeons and the fungus is indirect at best. The presence of pigeons may coincide with mold-friendly conditions, but they are not the cause. Blaming pigeons alone for spreading a naturally occurring mold is scientifically unfounded. The real issue is environmental hygiene, not avian biology.
Time of India
a day ago
- Time of India
'World near tipping point': Study warns about a deadly fungus that could kill millions
A new study has raised concerns about the possible spread of a deadly fungus across Europe, Asia, and the Americas due to rising global temperatures. The fungus, Aspergillus, thrives in warm and damp environments and could cause severe lung infections, especially in people with weakened immune systems or chronic respiratory illnesses. Risk of infection linked to warming climate Researchers say that Aspergillus could expand its reach as temperatures rise, making millions more vulnerable to its effects. The fungus is already known to grow in compost and other high-temperature settings. Its ability to survive at 37°C, the temperature inside the human body, allows it to infect the lungs of susceptible individuals. While not everyone who inhales its spores falls ill, people with asthma, cystic fibrosis, or weakened immunity are more likely to be affected. A global shift in species distribution Norman van Rhijn, a co-author of the study, warned that the world was approaching a "tipping point" regarding fungal pathogens. "We're talking about hundreds of thousands of lives, and continental shifts in species distributions. In 50 years, where things grow and what you get infected by is going to be completely different," Van Rhijn told the Financial Times. Live Events The study noted that Aspergillus fumigatus could potentially spread to 77% more territory by 2100 if fossil fuel use continues at the current rate. This would put an estimated nine million people in Europe at risk of exposure. Limited understanding of fungal pathogens Scientists say the danger is made worse by the fact that fungi are one of the least understood groups of organisms. Only around 10% of the estimated 1.5 to 3.8 million fungal species have been properly identified, and very few have had their genomes sequenced. "Its lifestyle in the natural environment may have provided Aspergillus fumigatus with the fitness advantage needed to colonise human lungs," said Professor Elaine Bignell, co-director at the MRC Centre for Medical Mycology at Exeter University. Drug development lags behind Despite the potential threat, investment in antifungal medicines has been slow. Scientists say this is due to high development costs and low expected returns, making it a less attractive area for pharmaceutical companies. The study also mentioned the fungus's ability to survive in extreme conditions, including the radioactive environment inside Chernobyl's nuclear reactors, which underlines its resilience.
Hans India
26-06-2025
- Hans India
Researchers turn toxic fungus into potent anti-cancer compound
A team of US researchers has turned a deadly fungus into a potent cancer-fighting compound, according to a new study. The result was a promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines, according to the study by University of Pennsylvania's School of Engineering and Applied Science. 'Fungi gave us penicillin. These results show that many more medicines derived from natural products remain to be found,' said Sherry Gao, Presidential Penn Compact Associate Professor in Chemical and Biomolecular Engineering (CBE) and senior author of a new paper in Nature Chemical Biology journal. The therapy in question is a class of ribosomally synthesized and post-translationally modified peptides, or RiPPs, pronounced like the 'rip' in a piece of fabric. The name refers to how the compound is produced — by the ribosome, a tiny cellular structure that makes proteins — and the fact that it is modified later, in this case, to enhance its cancer-killing properties. 'Purifying these chemicals is difficult,' says Qiuyue Nie, a postdoctoral fellow in CBE and the paper's first author. While thousands of RiPPs have been identified in bacteria, only a handful have been found in fungi. In part, this is because past researchers misidentified fungal RiPPs as non-ribosomal peptides and had little understanding of how fungi created the molecules. 'The synthesis of these compounds is complicated,' adds Nie. 'But that's also what gives them this remarkable bioactivity.' To find more fungal RiPPs, the researchers first scanned a dozen strains of Aspergillus, which previous research suggested might contain more of the chemicals. By comparing chemicals produced by these strains with known RiPP building blocks, the researchers identified A. flavus as a promising candidate for further study. Genetic analysis pointed to a particular protein in A. flavus as a source of fungal RiPPs. When the researchers turned the genes that create that protein off, the chemical markers indicating the presence of RiPPs also disappeared. This novel approach — combining metabolic and genetic information — not only pinpointed the source of fungal RiPPs in A. flavus, but could be used to find more fungal RiPPs in the future. Notably, the compounds had little to no effect on breast, liver or lung cancer cells — or a range of bacteria and fungi — suggesting that asperigimycins' disruptive effects are specific to certain types of cells, a critical feature for any future medication. The next step is to test asperigimycins in animal models, with the hope of one day moving to human clinical trials.
